Print
Email
Print Edition StoriesThursday, September 28, 2006
Novelos begins patient enrollment in hepatitis C trial
Newton-based Novelos Therapeutics Inc. reports the first patient has been enrolled in a hepatitis C trial with NOV-205, the company's second compound.
The initial U.S.-based double-blind, placebo-controlled Phase 1b trial will evaluate NOV-205 as monotherapy in 30 chronic hepatitis C genotype 1 patients who previously failed treatment with pegylated interferon plus ribavirin, company officials said.
Novelos is a biotechnology company developing therapeutics to treat cancer and hepatitis.
The World Health Organization estimates that chronic hepatitis C affects 170 million people worldwide and up to 4 million people are infected each year, Novelos reported.
Novelos was established in 1996 to commercialize oxidized glutathione-based compounds NOV-002 and NOV-205 for the treatment of cancer and hepatitis. It now employs six workers.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
